Brief: Diasorin Submits LIAISON NES Group A Strep Molecular Test To The U.S. FDA For 510(K) Clearance And CLIA Waiver
03/02/2026 11:23
Feb 3 (Reuters) - DiaSorin SpA DIAS.MI: SUBMITS LIAISON NES GROUP A STREP MOLECULAR TEST TO THE U.S. FDA FOR 510(K) CLEARANCE AND CLIA WAIVER Further company coverage: DIAS.MI (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on DiaSorin SpA
See all newsKepler sees European Medtech recovery, starts BioMerieux at 'Buy' as top pick
Brief: Diasorin Receives Us' FDA 510(K) Clearance And Clia Waiver For Liaison Nes Group A Streptococcus (Gas) Assay
Deutsche Bank cuts Diasorin to 'sell', sees company targets as stretched
Italy - Factors to watch on June 5
Italy's DiaSorin jumps after Betaville reports possible takeover interest